Mylan Inc. announced that the US Food and Drug Administration (FDA) has accepted for filing Mylan Pharmaceutical Inc.'s abbreviated new drug application (ANDA) for glatiramer acetate injection (20 mg/mL), a generic version of Teva's Copaxone, a product indicated for the treatment of multiple sclerosis.
The details can be read here.
No comments:
Post a Comment